May 2012
MondayMorning;5/21/2012, Vol. 20 Issue 21, p1
The article discuses financial performance of Dublin, Ireland-based firm Alkermes PLC. It has been informed that the firm reported huge loss in its fiscal fourth quarter in 2011 after buying drug technology unit of Elan Corp. PLC. It has also been informed that Alkermes has lost 63.4 million dollar or 49 cents per share in the three months which ended on March 31, 2012.


Related Articles

  • Elan Sells Remaining Alkermes Stake.  // Contract Pharma;Mar2013, Vol. 15 Issue 2, p131 

    The article reports on the sale of drug firm Elan Corp. PLC's remaining 7,750,000 shares from Alkermes PLC.

  • New EDT-Enlarged Alkermes Puts Down Roots in Dublin. Sheridan, Cormac // BioWorld International;9/21/2011, Vol. 16 Issue 38, p5 

    The article reports that Alkermes plc has completed its acquisition of Elan Drug Technologies (EDT), the drug delivery arm of Elan Corp. Following the acquisition, EDT has closed a manufacturing contract with a large pharmaceutical firm which will realize revenues of up to 20 million U.S....

  • Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary Shares Held by Elan.  // Biomedical Market Newsletter;3/14/2012, Vol. 21, p1 

    In this article, Alkermes plc. has announced the pricing of an underwritten public offering of 21,000,000 ordinary shares. It is mentioned that these shares were held at a price to the public of 16.50 dollars per share by a subsidiary of Elan Corp. plc. It further states that Citigroup Inc.,...

  • Elan Raises $381 Mln in Sale of 76% of Alkermes Holding.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article presents information that Elan Corp. PLC has raised net proceeds of 381 million U.S. dollars through the sale of 76 percents of its shareholding in Alkermes PLC. It informs that Elan will use this proceed for strengthening its capital structure and cash balances. A brief profile of...

  • Alkermes Files Resale Shelf Registration in Connection with Elan Shareholder Agreement.  // Biomedical Market Newsletter;2/21/2012, Vol. 21, p1 

    The article informs that Alkermes PLC has filed a resale shelf Registration Statement with the U.S. Securities and Exchange Commission ("SEC") regarding the future sales by a subsidiary of Elan Corp PLC ("Elan") of up to 31,900,000 ordinary shares of Alkermes PLC ("Alkermes"). Sale of these...

  • Alkermes plc Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article offers information related to an announcement made by Alkermes PLC. regarding commencement of its underwritten common stock public offerings held by its subsidiary Elan Corp. PLC. The bookings of the offering will be managed by Citigroup, Jefferies & Co. Inc. and Morgan Stanley and...

  • Other News To Note.  // BioWorld Today;2/ 4/2013, Vol. 24 Issue 23, p2 

    The article offers pharmaceutical news briefs as of February 4, 2013. Antabio SAS has received US$6.4 million Wellcome Trust Seeding Drug Discovery Award for the development of drug for the treatment of life-threatening infections caused by Gram-negative bacteria. U.S. Food and Drug...

  • Enzon: Seeking a Second Act. Quinn, William T. // njbiz;1/30/2006, Vol. 19 Issue 5, p3 

    Focuses on the decrease in sales posted by Enzon Pharmaceuticals and the drop of its drug research projects. Decrease in popularity of its antifungal drug Abelcet over products from bigger companies; Implications of the company's move to purchase rights for Abelcet from Elan in North America...

  • CORPORATE.  // MondayMorning;2/18/2008, Vol. 16 Issue 7, p2 

    This section offers news briefs in the pharmaceutical industry. AstraZeneca Plc is convinced it can prevail in U.S. patent disputes over its two biggest drugs, Nexium and Seroquel. Despite losses in the fourth quarter, Irish drugmaker Elan Corp. forecast a 30% rise in revenues over the coming...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics